Remote ischaemic conditioning for stroke: unanswered questions and future directions by Baig, S. et al.
This is a repository copy of Remote ischaemic conditioning for stroke: unanswered 
questions and future directions.




Baig, S., Moyle, B., Nair, K.P.S. et al. (3 more authors) (2021) Remote ischaemic 
conditioning for stroke: unanswered questions and future directions. Stroke and Vascular 





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
   1Baig S, et al. Stroke & Vascular Neurology 2021;0. doi:10.1136/svn-2020-000722
Open access 
Remote ischaemic conditioning for 
stroke: unanswered questions and 
future directions
Sheharyar Baig,1 Bethany Moyle,1 Krishnan Padmakumari Sivaraman Nair,2 
Jessica Redgrave,1 Arshad Majid,3 Ali Ali   4,5
1Cerebrovascular Medicine, The 
University of Sheffield Institute 
for Translational Neuroscience, 
Sheffield, UK
2Neurosciences, Sheffield 
Teaching Hospitals NHS 
Foundation Trust, Sheffield, UK
3Faculty of Medicine and 
Dentistry, University of Sheffield, 
Sheffield, UK
4Geriatrics and Stroke Medicine, 
Sheffield Teaching Hospitals 
NHS Foundation Trust, Sheffield, 
UK
5Sheffield NIHR Biomedical 
Research Centre, The University 
of Sheffield, Sheffield, UK
Correspondence to
Dr Ali Ali;  ali. ali@ sheffield. ac. uk
To cite: Baig S, Moyle B, 
Nair KPS, et al. Remote 
ischaemic conditioning for 
stroke: unanswered questions 
and future directions. Stroke 
& Vascular Neurology 2021;0. 
doi:10.1136/svn-2020-000722
 ► Prepublication history and 
additional material is published 
online only. To view please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ svn- 2020- 000722).
Received 29 October 2020
Revised 13 January 2021
Accepted 31 January 2021
Review
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Remote ischaemic conditioning (RIC) refers to a 
process whereby periods of intermittent ischaemia, 
typically via the cyclical application of a blood 
pressure cuff to a limb at above systolic pressure, 
confers systemic protection against ischaemia in 
spatially distinct vascular territories. The mechanisms 
underlying this have not been characterised fully but 
have been shown to involve neural, hormonal and 
systemic inflammatory signalling cascades. Preclinical 
and early clinical studies have been promising and 
suggest beneficial effects of RIC in acute ischaemic 
stroke, symptomatic intracranial stenosis and vascular 
cognitive impairment. Through systematic searches of 
several clinical trials databases we identified 48 active 
clinical trials of RIC in ischaemic stroke, intracerebral 
haemorrhage and subarachnoid haemorrhage. We 
summarise the different RIC protocols and outcome 
measures studied in ongoing clinical trials and 
highlight which studies are most likely to elucidate 
the underlying biological mechanisms of RIC and 
characterise its efficacy in the near future. We 
discuss the uncertainties of RIC including the optimal 
frequency and duration of therapy, target patient 
groups, cost- effectiveness, the confounding impact of 
medications and the absence of a clinically meaningful 
biomarker of the conditioning response. With several 
large clinical trials of RIC expected to report their 
outcomes within the next 2 years, this review aims to 
highlight the most important studies and unanswered 
questions that will need to be addressed before this 
potentially widely accessible and low- cost intervention 
can be used in clinical practice.
INTRODUCTION
Remote ischaemic conditioning (RIC) 
refers to the process by which cycles of 
temporary ischaemia, typically through 
the application of a manual or electronic 
tourniquet to a limb at above systolic 
blood pressure, confers a systemic protec-
tion against future ischaemic injuries in 
remote vascular territories,.1 The concept 
of ischaemic conditioning as a protective 
technique was described by Murry et al who 
found that 5 min cycles of occlusion and 
reperfusion of canine circumflex arteries 
repeated 4 times (4×5 mins) prior to 
experimental myocardial infarction in the 
same arterial territory led to a 25% reduc-
tion in myocardial infarct size compared 
with controls.2 Subsequently brief episodes 
of the same ischaemic conditioning 
protocol applied to the circumflex artery 
was found to have protective properties 
when the experimental infarct was induced 
in a different arterial territory3—RIC. It 
was later discovered that applying similar 
sublethal episodes of ischaemic to remote 
organs4 or a limb,5 also offered protec-
tion to subsequent ischaemic or reperfu-
sion injury, not only to the heart, but to 
other organs including liver,6 kidneys7 
and brain.8 These findings have led to the 
investigation of its use in cerebrovascular 
disease.
The timing of RIC in relation to isch-
aemia and subsequent reperfusion defines 
the terms preconditioning (RIPreC), 
perconditioning (RIPerC) and postcondi-
tioning (RIPostC) (figure 1). The protec-
tive effect of ischaemic conditioning occurs 
at different time frames: the acute effect 
is induced immediately and lasts 2 hours 
while the delayed protection occurs at 
12–24 hours, lasting upto 48–72 hours.9 
Furthermore, repeated cycles of RIC 
(chronic RIC) may induce distinct adapta-
tions that influence stroke recurrence and 
recovery.10 11
A small number of studies have investi-
gated the use of RIC in acute and chronic 
stroke,12–19 and have been summarised in 
recent review articles.20 21 However, there 
is a rapidly evolving research landscape 
with multiple ongoing clinical trials that, 
when completed and published, will have 
a significant impact on understanding the 
utility of RIC in stroke. Here, we outline 
the ongoing clinical trials investigating 
RIC in acute and chronic stroke, expand 
on the key remaining research questions, 
comprehensively detail the remaining 
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and make practice recommendations for future clin-
ical trial design.
METHODS
We searched the following trials registries/journals (25 
August 2020) for ongoing or completed trials of RIC in 
stroke:
1.  ClinicalTrials. gov (https:// clinicaltrials. gov/).
2. WHO International Clinical Trials Registry Platform 
(https://www. who. int/ ictrp/ search/ en/).
3. ISRCTN Registry (https://www. isrctn. com/).
4. European Union Clinical Trials Register (https://www. 
clin ical tria lsre gister. eu/).
5. BioMedCentral Trials Journal (https:// trialsjournal. 
biomedcentral. com/).
6. Chinese Clinical Trials Registry ( www. chictr. org. cn).
Search terms included ‘ischaemic conditioning’ and 
‘stroke’. In the Chinese Clinical Trials Registry ‘condi-
tioning’ was used as a search term to widen results. 
Further studies were identified from previous published 
articles and citation searches.
Active studies were included if the RIC intervention 
(cycles of temporary upper or lower limb ischaemia) was 
being studied in patients with stroke (ischaemic or haem-
orrhagic stroke), transient ischaemic attack or subarach-
noid haemorrhage. Completed studies were included 
if they met the search criteria above but had not yet 
published the full results.
Studies were labelled as having an ‘Unknown’ status 
if: (1) the study status was not available on the relevant 
clinical trials registry or (2) more than 2 years elapsed 
since the estimated completion date, without publica-
tion of results or trial registry update and (3) no email 
correspondence was received from chief investigator of 
the study.
Relevant studies
We identified 48 studies investigating RIC in stroke 
(online supplemental material). After analysing the trial 
protocols for each study, we determined that the RIC 
intervention is being studied in three distinct time frames:
1. RIPreC—the administration of RIC prior to a surgical 
or endovascular procedure where there is a significant 
risk of stroke.
2. RIPerC and/or early remote ischaemic postcondition-
ing (Early RIPostC)—the administration of RIC in the 
hours to days after the onset of an acute stroke (isch-
aemic, haemorrhagic or subarachnoid haemorrhage)
3. Chronic remote RIPostC (Chronic RIC)—the admin-
istration of repeated cycles of RIC for weeks to months 
in patients with a history of stroke.
Table 1 summarises the variety of populations, RIC 
protocols, outcome measures and estimated completion 
dates of ongoing clinical trials in RIC. A more detailed 
summary of individual studies can be found in online 
supplemental material.
RIPreC: The use of RIPreC is a clinical application 
of the classic paradigm of ischaemic preconditioning 
whereby a period of temporary ischaemia induces protec-
tive changes which reduce the impact of future sustained 
ischaemic insults.22 23 While the majority of strokes cannot 
be predicted, there are several clinical settings in which 
an ischaemic or haemorrhagic stroke is a potential conse-
quence of a surgical or endovascular procedure, for 
example, prior to treating cerebral aneurysms,24 carotid 
endarterectomy and carotid artery stenting.25
Three studies are investigating the potential benefit of 
RIPreC in reduction of ischaemic stroke or vasospasm 
after surgical and endovascular treatment of unruptured 
cerebral aneurysms (NEAT - NCT03496415; RIPAT - 
NCT0216265426; NCT03814850; online supplemental 
material).
The largest of these studies (NEAT - NCT03496415), 
from China, aims to recruit 210 participants from 
multiple centres, with unruptured intracranial aneu-
rysms, randomising them to bilateral upper limb RIPreC 
at 200 mm Hg or sham RIPreC at 60 mm Hg prior to 
neuroendovascular therapies (ET). The primary outcome 
measure of this study is the presence and volume of 
new DWI lesions on MRI within 72 hours of ET, while 
secondary outcomes include day 7 stroke severity (NIHSS 
score) and cerebrovascular events and modified Rankin 
Scale (mRS) at 30 days. Importantly, the participant, 
care provider, investigator and outcomes assessor are all 
masked to group allocation. The results from this study 
will indicate whether RIPreC has a potential role as an 
adjunct for elective aneurysm repair.
The RIPAT study (NCT02162654)26 aims to enhance 
our biomechanistic understanding of the potential bene-
fits of RIPreC before treatment of unruptured aneu-
rysms. This prospective, double- masked explorative trial 
in Austria, will randomise 48 individuals with asymptom-
atic intracranial aneurysms to RIPreC (3×5 min cycles in 
the upper arm at 200 mm Hg) or sham RIPreC (3×5 min 
cycles in the upper arm at 10 mm Hg), while measuring 
inflammatory cytokines associated with the conditioning 
response (S100 calcium- binding protein B (S100B), 
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Table 1 Summary characteristics of ongoing trials of RIC in stroke
Parameter No of studies
Study population   Ischaemic stroke/TIA 31
    Symptomatic intracranial stenosis 8
    Aneurysmal subarachnoid haemorrhage 4
    Unruptured cerebral aneurysm 3
    Intracerebral haemorrhage 3
Timing of conditioning   RIPreC 3
    RIPerC and early RIPostC 28
    Chronic RIPostC 16
    Unspecified 1
Participants (N)   <100 24
    100–500 17
    501–1000 4
    >1000 3
RIC protocol Cuff pressure 180 mm Hg 2
    200 mm Hg 26
    225 mm Hg 2
    20 mm Hg >SBP 4
    30 mm Hg >SBP 2
    50 mm Hg >SBP 1
    110 mm Hg >SBP 1
    Variable 1
    Unspecified 9
  Cycle length 3 min 1
    5 min 36
    10 min 1
    Variable 1
    Unspecified 9
  Cycle frequency 3 5
    4 16
    5 19
    Variable 1
    Unspecified 7
  Limb Upper 36
    Lower 5
    Unspecified 7
    Unilateral 18
    Bilateral 16
    Unspecified 14
Study location   Asia 30
    Europe 10
    North America 8
Primary outcome measures Clinical modified Rankin Scale 6
    Compliance/feasibility 6
    Adverse events 6
    Recurrent stroke 4
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Matrix Metallopeptidase 9 (MMP 9), Glial Fibrillar Acidic 
Protein (GFAP), Myelin Basic Protein, Neuron- Specific 
Enolase). Ischaemic lesions (number and volume) will 
be measured by DWI MRI at 12–48 hours post- treatment, 
with clinical outcomes (NIHSS and mRS) and neuropsy-
chological testing measured at 6 and 12 months. A caveat 
to this study is that two different procedures (endo-
vascular coiling and surgical clipping) are being used 
which may bias results. The current status of this trial is 
unknown, however, the results are of significant interest 
in developing our understanding of the temporal nature 
of the inflammatory cascade that follows RIPreC and 
assessing its potential impact on the development of peri- 
interventional ischaemia.
RIPerC and early RIPostC
We identified 28 studies investigating RIPerC and early 
RIPostC as an adjunct to hyperacute stroke care (online 
supplemental material). Putative beneficial mechanisms 
of RIC in this hyperacute setting include increased cere-
bral blood flow (CBF) and perfusion of the ischaemic 
penumbra.27 The primary aims for many of these studies 
are to establish whether RIPerC and/or early RIPostC is 
safe and can reduce stroke severity assessed by clinical and 
radiological indicators. Alongside this, several studies are 
investigating the feasibility of hyperacute RIC alongside 
intravenous thrombolysis (SERICT- AIS - NCT0402762128; 
rTPA- RIC - NCT02886390; rTPA- RIC1 - NCT03231384; 
TRIPCAIS - NCT03218293) and ET (PROTECT- I - 
NCT03915782; REVISE-2 - NCT03045055; RICE- PAC 
- NCT03152799). While the most trials are investigating 
whether RIC in ischaemic stroke, a subset of studies are 
investigating RIC in intracerebral haemorrhage and suba-
rachnoid haemorrhage (online supplemental material).
The largest study of RIC in acute stroke in Europe, 
the Danish RESIST trial (NCT03481777) will randomise 
1500 participants (baseline mRS ≤2) presenting within 
4 hours of symptom onset with a prehospital putative 
stroke (combined Cincinattti Prehospital Stroke Scale 
and Postural Assessment Scale for Stroke) to RIPerC/
sham in the prehospital phase and RIPostC/sham after 
6 hours in confirmed cases of acute ischaemic or haem-
orrhagic stroke. The active arm involves 5×5 min cycles 
of unilateral upper arm occlusion at 200 mm Hg (or 35 
mm Hg above SBP if baseline SBP is >175 mm Hg) while 
sham occlusion pressure rests at 20 mm Hg. The primary 
outcome measure of 3 month mRS will be supplemented 
with composite cardiovascular event rates at 3 months 
and 1 year, as well as quality of life measures and hospital 
bed- day use. Participants at the central site will also be 
randomised to RIPostC or sham RIPosC twice daily for 
7 days to facilitate an assessment of the incremental 
effect of repeated doses of RIC. In a subset of patients, 
the investigators will also assess the impact of RIC on 
DWI infarct growth at 24 hours (in ischaemic stroke) 
Parameter No of studies
    All- cause mortality 1
    NIHSS 1
    Walking speed 1
    Depression incidence 1
  Blood samples Serum biomarkers 5
    Immune profile 2
    Coagulation profile 1
  Radiological Infarct size/growth 6
    New infarcts 2
    Cerebral blood flow/collateral circulation 3
    Vasospasm 2
    Flow- mediated dilatation 1
  Other P300 event- related potential 1
    Cardiac function (echocardiogram) 1
Estimated study completion   2019 11
    2020 10
    2021 8
    2022 5
    2023 0
    2024 3
RIC, remote ischaemic conditioning; RIPerC, Remote ischaemic perconditioning; RIPostC, Remote ischaemic postconditioning; RIPreC, 
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and haematoma expansion on CT (in haemorrhagic 
stroke).
Other studies, such as RICAMIS (NCT03740971; 1800 
participants) and SERIC- AIS in China (NCT03669653; 912 
participants), REMOTE- CAT in Spain (NCT03375762; 
572 participants) and RESCUE- BRAIN in France 
(NCT02189928; 200 participants),29 will be of significant 
value in determining the relative efficacy of RIC in hyper-
acute stroke in different populations. However, there are 
important methodological differences in the study popu-
lations, inclusion criteria, timing and duration of RIC, and 
endpoints that may preclude the reliability of any future 
meta- analysis. The key differences between the large trials 
of RIC in acute stroke are summarised in table 2.
Chronic RIC
We identified 16 studies investigating the use of chronic 
RIC in patients with stroke (online supplemental mate-
rial), a large proportion of which concentrate on the 
secondary preventative effect in symptomatic intrac-
ranial atherosclerosis.15 16 However, a number of trials 
are also assessing the biological underpinnings of the 
protective action of RIC including platelet reactivity 
(NCT03635177) and CBF (PICASSO - NCT03208166, 
RICFAST - NCT03794947, NCT03635177, NCT02323425, 
NCT03589053, NCT03968068, ChiCTR1800014403). 
More novel studies are investigating the impact of RIC 
on walking (NCT04038697), skeletal muscle blood 
flow (NCT03635177), poststroke fatigue (RICFAST 
- NCT03794947) and poststroke depression (ChiC-
TR- OPC-17012871).
The largest study of chronic RIC is a multicentre trial 
in China (NCT02534545) where 3000 participants with 
symptomatic intracranial stenosis and a stroke or TIA 
(ABCD2 score ≥4) in the previous 30 days are randomised 
to either RIC (5×5 min cycles of bilateral upper limb 
occlusion at 200 mm Hg once daily for 12 months) or 
sham RIC (same protocol at 60 mmHg).30 With a primary 
end- point of time to first recurrence of ischaemic stroke, 
this study may definitively answer whether chronic RIC 
is an effective adjunct to aggressive medical therapy in 
patients with symptomatic intracranial stenosis.
With several large, multicentre trials of RIC due to 
report their findings within the next 3 years, there will be 
more robust data available on the efficacy of RIC in acute 
and chronic stroke. However, even if the efficacy of RIC is 
demonstrated, several outstanding uncertainties remain 
which require investigation in order to optimise the 
delivery of RIC to the most suitable target populations. 
Here, we discuss which ongoing studies can address these 




The minimally effective and most effective dose and 
frequency of RIC is unclear. With most studies employing 
between 3–5 × 5 minute cycles of upper limb ischaemia 
at 200 mm Hg once daily, a single ‘dose’ of RIC can last 
between 30 and 50 mins. Table 1 illustrates the variation 
in RIC protocols used in ongoing clinical trials. By iden-
tifying the dose–response relationship between RIC and 
any potential clinical benefits clinicians will be better able 
to counsel patients with shorter cycle lengths potentially 
resulting in improved concordance with therapy.
In addition to the RESIST trial, investigating single 
and repeated RIC in acute stroke, two further studies are 
investigating the optimal dose and frequency of chronic 
RIC (NCT03105141 and ChiCTR1800014403). In the 
first study, NCT03105141, 600 patients with symptomatic 
intracranial stenosis and a recent stroke or high- risk TIA 
are stratified into 1 of 10 treatment groups. All the treat-
ment groups receive automated RIC daily for 1 year with 
substudies assessing the effect of different cuff pressures 
(200 mm Hg or 40 mm Hg above systolic), cycle length 
(4, 5 or 6 mins), cycle number (4, 5 or 6) and frequency 
(once daily vs twice daily) on stroke recurrence. At the 
same centre, ChiCTR1800014403 will randomise 273 
individuals with symptomatic intracranial stenosis to 
either 3×3 mins or 5×5 mins cycles of RIC twice daily 
and compare the effect of a shorter RIC intervention on 
secondary prevention. Timing of RIC in Acute Stroke: 
The optimal timing of RIC delivery in acute stroke is 
unclear. Among the major trials of RIC in acute stroke 
there is significant heterogeneity in patient inclusion 
criteria and the timing of RIC (table 2). For instance, in 
RICAMIS (NCT03740971) only acute moderate- severe 
ischaemic stroke (National Institute of Health Stroke 
Scale, NIHSS 6–16) cases confirmed on neuroimaging 
and within 48 hours of symptom onset are included while, 
in the RESIST study (NCT03481777), RIC is commenced 
in a prehospital phase for patients with a presumed stroke 
(based on the combined Cincinnati Prehospital Stroke 
Scale and Postural Assessment Scale for Stroke) within 
4 hours of symptom onset. A schematic of the timing 
and duration of RIC in the larger acute stroke trials is 
illustrated in figure 2. If the beneficial effects of RIC in 
acute stroke require early intervention, then adequately 
powered studies of RIC delivered in the prehospital phase 
are essential to establish its efficacy.
Duration: It remains unclear whether there is a ceiling 
effect of repeated, daily RIC; if RIC is still efficacious 
when delivered on a less frequent basis, this may increase 
uptake and concordance. In chronic stroke, RIC has been 
used daily for up to 300 days.15 Meng et al reported on a 
proof- of- concept study of twice daily bilateral upper limb 
RIC for 300 days in patients with symptomatic intracra-
nial stenosis. Those in the treated arm (n=38) experi-
enced significant reductions in stroke recurrence after 
90 and 300 days of RIC compared with controls treated 
with medical therapy alone (n=30).15 The Kaplan- Meier 
analysis of stroke recurrence indicates deviation of RIC 
group from controls after around 60 consecutive days 
of RIC, however, it is unclear whether a shorter dura-






















































































































































Table 2 Summary of the major clinical trials of RIPerC and early RIPostC in acute stroke
Study N Population and timing











1800 Acute moderate ischaemic stroke 
(NIHSS 6–16), confirmed on CT/MRI, 











All- cause mortality day 90






1500 Acute ischaemic stroke and 
acute intracerebral haemorrhage, 
Prehospital Stroke Score ≥1* and 
within 4 hours of symptom onset.
RIC commenced at prehospital 






Up to 7 days
Sham RIC at 
20 mm Hg
mRS at day 
90
Prehospital stroke score at 24 hours.
All cause mortality at 1 year
Biomarkers: nitric oxide synthase 






912 Clinical diagnosis of acute ischaemic 
stroke (NIHSS 5–25) and within 12 





Up to 7 days
Sham RIC 
(60 mm Hg)






572 Suspected clinical stroke (RACE scale 
>0 and RACE motor item >0) and 







mRS day 90 NIHSS day 5
Infarct volume (DWI MRI)





200 Clinical diagnosis of ischaemic stroke 
and within 12 hours of symptom 
onset
4×5 mins
(20 mm Hg >SBP)
Unilateral UL
Twice daily
Up to 4 days
Sham RIC at 
50 mm Hg
Infarct size 
on DWI MRI 
at day 4/day 
of discharge 
if earlier
mRS at 12 weeks
NIHSS at discharge







200 Acute ischaemic stroke (NIHSS 5–25), 
confirmed on MRI and within 6 hours 
of symptom onset
4×5 mins
(110 mm Hg >SBP)
Unilateral LL
Single treatment
Usual Care Infarct growth 
on DWI MRI 
at 24 hours
NIHSS day 1
mRS and Barthel Index at 12 months
Recanalisation rates after 
thrombolysis/thrombectomy
*The Prehospital Stroke Score is a combined score of the Cincinnati Prehospital Stroke Scale and Postural Assessment Scale for Stroke mRS.
BDNF, Brain- derived Neutrotrophic Factor; DWI, Diffusion Weighted Imaging; HIF- 1a, Hypoxia- inducible Factor 1- alpha; IL-6, interleukin 6; mRS, modified Rankin Scale; NIHSS, National 
Institute of Health Stroke Scale; RACE, Rapid Arterial Occlusion Evaluation; RIC, remote ischaemic conditioning; SBP, systolic blood pressure; SSQoL, Stroke Specific Quality of Life Scale; 
SSQoL, Stroke Specific Quality of Life ; TNFα, tumour necrosis factor-α; TOPICS- SF, The Older Persons and Informal Caregivers Short Form; TOPICS- SF, The Older Persons and Informal 
Caregivers Survey Short Form; VEGF, Vascular Endothelial Growth Factor.
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sustain a clinically beneficial effect over the long term. 
The maximum follow- up time in current RIC studies is 
12 months, which may be suboptimal given the follow- up 
times required to prove effectiveness in secondary preven-
tion trials of antiplatelets and statins.31 32 Taken together, 
this could help establish an agreed protocol of either a 
single course of RIC, periodic RIC or lifelong RIC. Both 
the use of RIC for stroke prevention, potentially lifelong, 
and long term trial follow- up, are significant investments 
for patients and trialists, respectively. The discovery 
of validated biomarkers for vascular protection could 
shorten follow- up times and identify patients responding 
to treatment, negating the need for unnecessary long 
term treatment.
Unilateral versus bilateral RIC
While bilateral RIC may theoretically produce a larger 
ischaemic stimulus, no study is currently comparing the 
clinical impact of unilateral vs bilateral RIC. Unilateral 
RIC may be more convenient for individuals with hemip-
aresis and may allow concurrent completion of daily tasks 
during therapy. Furthermore, in the context of hypera-
cute stroke, the use of unilateral RIC enables the other 
arm to be used for venous access and intravenous throm-
bolysis.
For unilateral RIC, it is unclear if the marginal gain from 
repeated conditioning in the same limb diminishes over 
time. As such, it would be helpful to establish whether 
alternating the site of delivery has a role in maintaining 
the conditioning stimulus over time. Furthermore, it is 
unclear whether the use of unilateral RIC in the paretic 
arm yields the same conditioning response as RIC in the 
non- paretic arm; experimentally, nerve transection has 
been shown to block the effect of preconditioning,33 
however, this has not been established for organic central 
lesions.
Upper limb versus lower limb RIC
While lower limb RIC has the theoretical potential to 
induce a larger ischaemic stimulus, a study of RIC in 
healthy volunteers showed no significant differences in 
the production of nitrite, a potential signalling mediator 
of the conditioning response, after upper limb or lower 
limb RIC in healthy volunteers.34 However, as discussed, 
given the conditioning response likely involves multiple 
signalling cascades that occur over different time frames, 
there is insufficient evidence to conclude that upper limb 
and lower limb RIC are equipotent. We found only five 
studies investigating lower limb RIC (RESCUE- BRAIN 
(NCT02189928),29 PreLIMBS (NCT02411266), RIPC- SAH 
(NCT02381522), NCT04039399, NCT04038697). The 
preponderance of interventions using upper limb RIC 
may reflect increased practicality for both patients and 
carers. A qualitative analysis of patient experience with 
both upper and lower limb RIC may reveal key barriers to 
longer- term compliance that can help investigators opti-
mise intervention strategies.
Safety and tolerability
Multiple clinical trials suggest that RIC is safe,20 21 even 
when performed twice daily on both arms for 300 days,15 
including in the elderly.16 However, relatively few studies 
of chronic RIC have reported on compliance, therefore, 
it is difficult to ascertain whether stroke patients are 
able to carry out RIC for sustained periods of time. In 
Meng et al,15 51 patients with symptomatic intracranial 
stenosis were randomised to receive twice daily bilateral 
arm conditioning for 300 consecutive days but only 38 
(74.5%) completed the study. Long- term data on larger 
cohorts will help inform clinicians on likely compliance 
rates.
A small number of side effects have been reported 
including skin petechiae,16 but no studies have indicated 
increased risks of venous thrombosis or rhabdomyolysis. 
It is unclear if chronic RIC affects sensory or motor func-
tion of the conditioned limbs; studies that include these 
detailed clinical and electrophysiological assessments as 
outcome measures should help fill this knowledge gap.
A consistent exclusion criterion for several clinical trials 
of RIC in stroke has been known peripheral vascular 
disease or venous thromboembolism affecting the condi-
tioned limb. While there is a theoretical risk of harm in 
these patients, the fact that prior studies have not high-
lighted incident risk of these complications, and that 
studies are investigating upper limb RIC in patients with 
known lower limb peripheral arterial disease,35 should 
provide some reassurance to clinicians.
RIC and ET
The usefulness of RIC alongside ET for large vessel 
occlusion (LVO) has attracted much research interest. 
Numerous questions arise. The first is whether RIC can 
be delivered parallel to ET without causing significant 
treatment delays. The second is whether, RIC performed 
alongside recanalisation of a culprit vessel may influence 
cerebral autoregulation in a manner that increases the 
risk of reperfusion injury or haemorrhagic transforma-
tion. Hypertension and impaired cerebral autoregulation 
Figure 2 A schematic of RIC timing and duration in major 
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often already accompany acute ischaemic stroke.36 37 The 
third is whether the effect of general anaesthetic dimin-
ishes the effect of RIC; as previous studies have indicated, 
the use of propofol inhibits the ischaemic conditioning 
response.38
Manual versus automated RIC
Automated RIC devices are widely available. While RIC 
has been marketed as a potentially low- cost, non- invasive 
intervention for vascular diseases, the costs of obtaining 
multiple devices, cuff and battery replacements, may prove 
to be prohibitively expensive in low and middle income 
countries where the rates of cerebrovascular disease 
remain high.39 As such, studies which deploy manual RIC 
(with sphygmomanometers and digital timers) will help 
develop the global translatability of RIC.
Three studies plan to compare the effect of RIC in those 
undergoing ET (REVISE-2 - NCT03045055, PROTECT- I 
- NCT03915782, RICE- PAC - NCT03152799) (online 
supplemental material). As well as revealing efficacy, 
these will highlight the practical challenges of delivering 
RIC to patients in a time- sensitive manner.
Target populations
Intracranial stenosis: The majority of studies of chronic 
RIC have been performed in individuals with significant 
intracranial stenosis. This is an important population to 
study for two reasons: high stroke recurrence rates in this 
population mean a lower sample size is needed to detect 
a significant treatment effects, and they are a subgroup 
where significant improvements in care can potentially 
be made. However, while intracranial atherosclerosis 
contributes to ischaemic stroke in a large proportion of 
individuals globally, it is a less common mechanism of 
stroke in European and North American populations 
where extracranial carotid disease, cardioembolic stroke 
and small vessel disease are more common.40 41 As such, 
studies need to extend to individuals without intracra-
nial stenosis to establish the utility of RIC in the wider 
setting of secondary stroke prevention. Furthermore, 
most studies of chronic RIC in ischaemic stroke have 
been performed in East Asia; while there is no identifi-
able reason why the response to RIC would be different in 
a different population, it is important for similar studies 
to be undertaken outside of Asia to identify whether the 
chronic RIC is both tolerated and beneficial in a wider 
global setting.
The influence of comorbidities and medications: It 
is recognised that the impact of RIC may diminish with 
age.42 However, Meng et al,16 demonstrated that RIC 
may reduce stroke recurrence in those over 80 thereby 
suggesting that ageing alone may not suppress the bene-
ficial effects of RIC.
Diabetes mellitus is a common risk factor for ischaemic 
stroke, however, evidence from both animal models 
and clinical studies suggest that diabetes, particularly 
diabetic neuropathy, may abolish the protective effect of 
RIC.43 For instance, a recent study of chronic, daily RIC 
in patients with diabetes with peripheral arterial disease 
failed to show any positive impact on vascular or neuronal 
function35; potentially linked to impairment of the neuro-
genic pathways thought to potentiate the action of RIC.43 
The theoretical risk of compounding nerve damage with 
repeated limb compression in chronic RIC may also be a 
reason for excluding such patients from trials, and their 
ultimate under- representation in the literature. Subgroup 
analyses of larger randomised controlled trials or pooled 
datasets may help determine if the presence of diabetes 
truly impacts on the clinical effects of RIC.
Animal models also suggest that the conditioning 
response is diminished by the presence of comorbidi-
ties such as hypercholesterolaemia, hypertension and 
obesity.42 However, this has not yet been confirmed in 
clinical studies of RIC in stroke. Similarly, several medi-
cations that are commonly prescribed in individuals with 
cardiovascular disease including nitrates, atorvastatin and 
nicorandil may activate similar intracellular signalling 
cascades to RIC.44 However, clinical data are lacking with 
respect to understanding whether this would potentiate 
or abrogate the effects of RIC in patients taking these 
medications.
Cardioembolic stroke
Studies of RIC in ischaemic stroke typically exclude indi-
viduals with known cardioembolism from causes such as 
atrial fibrillation or flutter. In these patients, stroke often 
results from the sudden migration of thrombus from the 
heart to the cerebral arteries, a pathway that RIC may not 
obviously affect at first glance. However, the impact of 
RIC on secondary prevention of cardioembolic stroke is 
of interest for several reasons. First, the seminal studies 
investigating the protective effect of ischaemic precon-
ditioning were performed in animal models where 
ischaemia was precipitated acutely,22 23 a mode of infarc-
tion more akin to cardio- embolism than atherosclerotic 
disease. It may be that slow atheromatous progression 
and intracranial stenosis leads to a degree of endoge-
nous pre- conditioning that reduces the marginal impact 
of RIC compared with those with cardio- embolic stroke. 
Consistent with this, previous studies have indicated that 
the volume of ischaemia resulting from cardioembolism 
is larger than that due to a similar sized clot from the 
carotid/intracranial circulation.45 Furthermore, the most 
common cause of cardio- embolism, atrial fibrillation, 
develops predominantly in later life and in the context 
of cardiovascular risk factors such as hypertension and 
diabetes mellitus. As such, many patients with atrial fibril-
lation have associated endothelial dysfunction,46 another 
pathway potentially impacted by RIC.47
Small vessel ischaemic disease
Small vessel ischaemic disease (SVID) is a common 
comorbidity and complication associated with stroke and 
is a precursor for the development of vascular cognitive 
impairment (VCI) and vascular dementia. The role of RIC 
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CBF and inflammatory markers. In SVID, hypoperfusion 
due to microangiopathy can precipitate neurodegenera-
tion through disruption of the blood–brain barrier and 
neuroinflammation.48Declines in cognitive function have 
also been associated with reduced microvascular perfu-
sion.49 Small pilot studies of patients with established 
SVID or those with VCI have shown that RIC applied 
twice daily (5×5 min cycles) for between 6 and 12 months 
can result in improvements in CBF velocities, reductions 
volume of white matter lesions, and variable improve-
ments in domains of cognitive function.50–52 Investiga-
tions are currently under way to evaluate whether once 
daily application, for a shorter duration of 1 month has 
similar effects with greater treatment adherence.53
RIC and exercise
Experimental and clinical evidence suggests shared 
biological mechanisms for the effects of RIC and exercise, 
including increased heat shock proteins and increased 
endothelial nitric oxide signalling.54 It is unclear whether 
there is any synergistic effect of RIC when performed in 
addition to regular exercise, and no current studies evalu-
ating this in chronic stroke. While exercise confers many 
physiological benefits in stroke patients,55 numerous 
barriers to exercise poststroke exist including depression, 
fatigue and physical disability. As such, if there are physi-
ological effects of RIC that mirror exercise, then this may 
be a useful long- term ancillary treatment when patients 
are physically unable to exercise.
Underlying mechanism and biomarkers
Applying an external pressure to occlude blood flow to 
a limb initiates transmission of a signal that mediates 
the RIC response. Humoral, neurogenic and immune 
mediated pathways have been proposed as transmission 
and end organ effector mechanisms.9 After the transmis-
sion of the conditioning stimulus, an array of possible 
biochemical and physiological changes may contribute 
to clinically meaningful outcomes in stroke patients 
including increased CBF,15 angiogenesis and increased 
collateral circulation,27 antiplatelet effects,56 57 synapto-
genesis,58 immune regulation, mitochondrial function 
and autophagy regulation,47 (figure 3). The latency of 
these biological mediators and effectors may vary and 
are likely to underpin differences in effects of acute and 
chronic RIC.9 Establishing the underlying mechanisms 
and final effectors of RIC will prove essential in opti-
mising intervention development, trial design and estab-
lishing its efficacy and safety in wider clinical practice. 
Furthermore, by characterising the intracellular pathways 
associated with the beneficial effects of RIC, appropriate 
drug targets may be identified, leading the way towards 
pharmacological conditioning.59
For subarachnoid haemorrhage, the putative biological 
mechanism for any potential benefit of RIC are not well 
characterised but may involve reducing vasospasm.60 In 
intracerebral haemorrhage, there are pathophysiolog-
ical consequences that are shared with ischaemic stroke 
including endothelial dysfunction, impaired cerebral 
autoregulation, a proinflammatory mileu and mito-
chondrial dysfunction61; these have all been proposed 
as therapeutic targets of RIC in ischaemic stroke, and 
therefore, may prove to be of significance in intracerebral 
haemorrhage.
Circulating biomarkers
Previous studies have indicated potential serum signal-
ling mediators of RIC including heat shock proteins, 
tumor necrosis factor (TNF)-α and interleukin 6 (IL-6).9 
However, no established circulating biomarkers have 
been shown to be reliably correlate with the degree of 
conditioning response or clinical outcomes. Identifying 
a serum biomarker would be advantageous as it could 
offer a minimally invasive measure to: (1) establish which 
patients are responding to the treatment and (2) opti-
mise the dose, frequency and duration of RIC treatment 
on an individualised basis. Several ongoing studies are 
investigating candidate circulating biomarkers including 
Figure 3 Proposed mechanism of action of remote 
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NCT02323425 (VEGF and bFGF), RESIST - NCT03481777 
(eryNOS3 phosphorylation, microRNA and extracel-
lular vesicle profile), NCT03546309 (S100- A4, MMP-9, 
bFGF, PDGF, VEGF) and NCT03335111 (IL-4, IL-6, TNF) 
(online supplemental material). Future studies of RIC 
in stroke should include focused analyses of candidate 
biomarkers, identified from experimental animal and 
human models, at different time points before, during 
and after both acute and chronic RIC. It is also impor-
tant to validate which biomarkers are associated with the 
transmission of the ischaemic signal and which are asso-
ciated with the biological effector response and clinical 
outcomes.
Radiological correlates
Animal models,27 and previous clinical studies,15 indi-
cate that RIC can increase CBF as well as increasing the 
dynamic range of cerebral autoregulation in healthy 
volunteers.37 In the setting of acute ischaemic stroke, 
RIPerC may increase CBF (directly or via collaterals) 
to salvage the ischaemic penumbra.27 Several studies 
are investigating the effect of RIPerC on infarct volume 
and clinical outcomes acutely (online supplemental 
material), however, few trials use non- invasive measures 
such as Transcranial Doppler (TCD) to characterise 
the impact of RIC on blood vessel diameter and flow. 
Several studies investigating chronic RIC are measuring 
cerebral and skeletal muscle blood flow using a range of 
modalities including TCD, Arterial Spin Labelling and 
MR angiography (NCT03635177, NCT02323425 and 
NCT04038697). If increased cerebral or skeletal muscle 
blood flow is associated with positive clinical outcomes in 
the larger studies of chronic RIC then non- invasive assess-
ments of blood flow could be used to establish response 
to RIC on a personalised level.
Economic analysis
The costs of automated conditioning devices, device 
maintenance and safety monitoring need to be factored 
into a cost–benefit analysis of RIC in stroke. Furthermore, 
additional care staff may be required to administer RIC 
to individuals who are unable to independently apply the 
device.
Recommendations for future trial design
Given the multitude of ongoing studies for RIC in stroke, 
a collaborative effort is required to synthesise the array 
of results into meaningful outcomes for stroke patients. 
Figure 4 represents a proposed schema for future clin-
ical trial design, identifying six key areas which future 
studies should focus their attention in order to address 
the remaining uncertainties of RIC in stroke.
CONCLUSIONS
RIC has been shown to be a promising therapy in animal 
models of stroke while smaller clinical studies have indi-
cated its safety and feasibility in humans. However, there 
are several remaining questions before results of these 
studies can be translated into widespread clinical practice. 
Ongoing clinical trials will inform whether RIC is effec-
tive in the acute and chronic setting of stroke. However, 
there is an urgent need to concurrently investigate which 
patient groups respond best to RIC, identify the optimal 
dose and duration of therapy, and to establish biological 
and radiological biomarkers of the conditioning response 
before RIC can advance into routine clinical practice.
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Figure 4 Optimising remote ischaemic conditioning (RIC) 
trial design. AIS, Acute Ischaemic Stroke; ET, endovascular 
therapy; ICH, Intracerebral haemorrhage; SAH, Subarachnoid 
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Supplementary material 1. Ongoing Studies of Remote Ischaemic Conditioning (RIC) in Stroke  
 
Study Status  
 
Population N RIC Protocol Control 
Group(s)  
Primary Outcome Selected Secondary 
Outcome Measures  





Recruiting Unruptured  




Sham RIC  
(60mmHg) 
New DWI lesions day 3 Ischaemic lesion burden 
NIHSS day 7  







CA pre-ET  
50 4 x 5 mins 
(30mmHg > 
SBP)  
Unilateral UL  





Cognitive impairment day 2-4 
and 9 months 
 







Unknown  Unruptured 
CA pre-
ET/surgery 
48 3 x 5 mins 
(200mmHg) 
Unilateral UL  
Sham RIC   
(10mmHg) 
Biomarkers (S100B, 
NSE, GFAP, MMP9, 
Microparticles) 
New ischaemic lesions day 1-
2 
 
NIHSS and mRS at 12 
months 














DWI MRI infarct 
volume at 24 hrs  
mRS day 90  
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Usual care  mRS day 90 NIHSS day 12 
Stroke associated pneumonia 
All cause mortality day 90 
Biomarkers (BDNF, VEGF, 













up to 7 days    
Sham RIC 
(20mmHg)  


















Infarct volume day 1 
(FLAIR)  
NIHSS day 7  













7 days  
Sham RIC  mRS day 90 Adverse events 








AIS + MT  
 






Final CT infarct volume  Trial feasibility 
mRS day 9  














MRI DWI infarct 
volume day 4 (or day of 
discharge)  
NIHSS at discharge 
mRS day 90 




RICH Recruiting  Acute sICH  40 4 x 5 mins Usual Care Adverse events   
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Recruiting  Suspected 
AIS  
572 5 x 5 mins 
Unspecified 






mRS day 90  Early NIHSS change 
Infarct volume (DWI MRI)  

















mRS day 90 NIHSS day 7  










24hrs post tPA 
Sham RIC 
(60mmHg) 
Adverse events NIHSS day 7 or discharge  










tPA alone  MRI DWI infarct 
volume at 72 hours 
NIHSS day 5-7 
mRS day 90 
Recurrent events day 90 
MMP-9, IL-6, HS-CRP at 





Completed AIS + tPA 31 5 x 5 mins 
(200mmHg)  
Bilateral UL  
tPA alone Feasibility  Signs of tissue or 
neurovascular injury 
Infarct volume (MRI) day 7  
NIHSS day 7  
mRS day 90 




Age ≥ 60 
AIS + ACS  
80 5 x 5 mins 
(200mmHg) 
Sham RIC  
(60mmHg) 
All cause mortality at 3 
months 
NIHSS day 90 
GRACE score day 90 
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 Bilateral UL 











Usual care Flow cytometry 
(immune profile)  
Serum cytokines at baseline, 
day 2 and day 7 (TLR-2, IL-
6)  









cuff pressure)  
Bilateral UL 
Usual care VEGF, bFGF up to 12 
months  
NIHSS day 14 











10 3-5 x 5 mins 
(200mmHg)  
Bilateral UL   








for 7 days  
Sham RIC 
(60mmHg) 
Serum cytokines and 
peripheral immune cells 
at baseline, day 1 & day 
7. 
NIHSS day 7 










60 Not specified  Usual care Cardiac function (ECG, 
Echo, serum markers) 
mRS at discharge, 30 days 





Completed AIS  44 Not specified  Sham RIC 
(unspecified 
pressure)  
Stroke progression day 
90  
mRS, NIHSS, vascular events 
and mortality day 90  
ChiCTR-IOR-
1500654964   
Recruiting  AIS  400 
 




Feasibility Infarct volume  
mRS 
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30 mins AE 
 



















l SAH   












(S100B, NSE)  






l SAH  




Unilateral LL  
every 1-2 days 
for 14 days  
Sham RIC  
(30mmHg)  





Recruiting  Ruptured 




Bilateral UL  
Sham RIC 
(60mmHg)  
Ischaemic lesions (MRI 
DWI) at 72 hours 
NIHSS day 7  
Cerebrovascular events day 
30  
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l SAH  




















Unknown  AIS 
(anterior 
circulation) 






Sham RIC  Penumbral salvage 
(MRI) at 3 months 
Cerebral oedema and infarct 
size day 7  
mRS, NIHSS and QoL at 3 
months  
ChiCTR-INR-













mRS at 12 months  
Recurrent ischaemic stroke  






Completed NDS or 
high-risk 
TIA  
167 5 x 5 min  
(200mmHg) 
Bilateral UL  
Twice daily  







Handgrip strength in affected 
arm at day 90  




Recruiting  Lacunar 
stroke  
20 Crossover: 




4 weeks  
Crossover: 
Sham RIC  
FMD (brachial artery)  Femoral artery blood flow 
before and after exercise 
CBFv during visual task  










Usual care Collateral circulation at 
6 months (MRA, DCE-
MRI, TCD, SPECT) 
NIHSS at 1 year  
VEGF and bFGF day 10  
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Twice daily 


















Cold Pressor Test and 
plasma epinephrine & 
norepinephrine  
SBP after RIC and cold 











120 5 x 5 mins 
(225mmHg) 
Unilateral LL  
(Paretic Leg) 
12 sessions 























Knee extensor strength 
FMD of non-paretic brachial 
artery 














12 months  
Sham RIC 
(60mmHg)  
Time to recurrent stroke All cause mortality 












34 4 x 5 mins 
(200mmHg) 
Unilateral UL  
18 sessions 
over 6 weeks  
Sham RIC 
(20 mmHg)  
Feasibility 
Adverse events  
  
FSS 6 weeks 
 




ChiCTR- Recruiting  sIntraCAS  273 5 x 5 min  3 x 3 min  Recurrent stroke/TIA at NIHSS, mRS and BI at 12 
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90 days  
Sham RIC   CBF and brain 
metabolism under stress  





Completed  sIntraCAS 2 4 x 5 mins 
(200mmHg) 
Bilateral UL 
Daily 30 days  
Usual care CBF (MRI ASL) day 
30 
Feasibility  
Biomarkers at day 30 
(including Nitrite, IL-10, hs-










60 4 x 5 mins 
(Unspecified 
cuff pressure) 
Once or twice 
daily 
One year 











of cycles,  
cycle lengths, 
frequency and 




Recurrent stroke at 12 
months  
Adverse events  
Cerebral perfusion   
(multi-modal) 
Cognition (MMSE, MOCA, 
TICS-M)  
ChiCTR190002 Not yet sIntraCAS 140 Not specified  Sham RIC NIHSS, mRS & BI day Vascular events day 180 
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Key: 
10MWT – 10 meter walk test 
ACS – Acute Coronary Syndrome 
ADL – Activities of daily living 
AE – Aerobic exercise 
AIS – Acute Ischaemic Stroke 
1006   
China 
2019 
recruiting  (unspecified 
pressure)   
180 
 









& sCAS  






Usual care Combined vascular 
events at 1 year  
Time to vascular event 
All cause mortality at 1 year  





Unknown  sIntraCAS 80 5 x 5 mins  
(200mmHg) 
Bilateral UL  
Twice daily  
Unspecified 
duration 
Usual care Posterior circulation 
stroke at 6 months  
Combined cerebrovascular 
events at 6 months 
mRS at 6 months  





Unknown  Ischaemic 
stroke  
50 Daily RIC (not 
further 
specified)  






Recruiting  AIS  104 Not specified  
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AIS + MT – Acute Ischaemic Stroke plus Mechanical Thrombectomy  
ASL – Arterial spin-labeled 
BDNF – Brain-derived neurotrophic factor  
BI – Barthel index 
bFGF – Basic Fibroblast Growth Factor 
CA – Cerebral aneurysm 
CBF(v) – Cerebral blood flow (velocity) 
DCE-MRI – Dynamic Contrast-Enhanced Magnetic Resonance Imaging  
DWI – Diffusion Weighted Imaging 
ET – Endovascular Therapy  
FMD – Flow Mediated Dilatation 
FSS – Fatigue Severity Score 
GOSE – Extended Glasgow Outcome Scale 
GFAP – Glial Fibrillary Acidic Protein 
HDS – Hamilton Depression Scale 
HIF-1α – Hypoxia-inducible Factor 1-Alpha 
HSP – Heat shock proteins 
HS-CRP – High Sensitivity C Reactive Protein 
ICAM-1 – Intracellular Adhesion Molecule 1 
ICH – Intracerebral Haemorrhage 
IL-1β – Interleukin 1 Beta  
IL-4 – Interleukin 4 
IL-6 – Interleukin 6  
IL-10 – Interleukin 10 
LL – Lower Limb 
LVO – Large Vessel Occlusion 
MMP-9 – Matrix metalloproteinase-9 
MFI – Multidimensional Fatigue Inventory 
MMSE – Mini-Mental State Examination  
MOCA – Montreal Cognitive Assessment 
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mRS – Modified Rankin Scale  
NDS – Non-disabling Stroke 
NIHSS – National Institutes of Health Stroke Scale  
NSE – Neuron-Specific Enolase  
QoL – Quality of Life Assessment  
S100B – S100 calcium-binding protein B  
SAH – Subarachnoid Haemorrhage  
SBP – Systolic Blood Pressure  
sIntraCAS – Symptomatic Intracranial Atherosclerosis  
sCAS – Symptomatic Coronary Artery Stenosis 
SPECT – Single Photon Emission Computed Tomography 
TCD – Transcranial Doppler  
TEG-MA – Thromboelastography 
TIA – Transient Ischaemic Attack  
TICS-M – Modified Telephone Interview for Cognitive Status 
TLR-2 – Toll-like Receptor 2 
TNFα – Tumour Necrosis Factor Alpha 
tPA – Tissue Plasminogen Activator (Intravenous Thrombolysis)  
UL – Upper Limb 
VEGF – Vascular Endothelial Growth Factor  
 
62. Li X-Q, Tao L, Zhou Z-H et al. Remote ischemic conditioning for acute moderate ischemic stroke (ricamis): Rationale and design. International Journal of Stroke.0:1747493019879651 
63. Landman T, Schoon Y, Warlé M et al. The effect of repeated remote ischemic postconditioning on infarct size in patients with an ischemic stroke (repost): Study protocol for a randomized clinical trial. Trials. 
2019;20:167 
64. Li Y, Liang K, Zhang L et al. Upper limb ischemic postconditioning as adjunct therapy in acute stroke patients: A randomized pilot. Journal of Stroke and Cerebrovascular Diseases. 2018;27:3328-3335 
65. Sangeetha RP, Ramesh VJ, Kamath S et al. Effect of remote ischemic preconditioning on cerebral vasospasm and biomarkers of cerebral ischemia in aneurysmal subarachnoid hemorrhage (ervas): A 
protocol for a randomized, controlled pilot trial. Brain circulation. 2019;5:12-18 
66. Liu SM, Zhao WL, Song HQ et al. Rationale and study design for a single-arm phase iia study investigating feasibility of preventing ischemic cerebrovascular events in high-risk patients with acute non-
disabling ischemic cerebrovascular events using remote ischemic conditioning. Chinese Med J-Peking. 2018;131:347-351 
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Supplementary material 2. Serum biomarkers under investigation as mechanistic markers 
of the effects of Remote Ischaemic Conditioning in Stroke. 
 
Serum Biomarker Study 
S100B RIPAT (NCT02162654)26, ERVAS58 
NSE RIPAT (NCT02162654)26, ERVAS58 
GFAP RIPAT (NCT02162654)26  
MMP-9 RIPAT (NCT02162654)26, rTPA-RIC 
(NCT02886390), PICASSO (NCT03208166)  
BDNF RICAMIS (NCT03740971)55 
VEGF RICAMIS (NCT03740971)55, TRIPCAIS 
(NCT03218293), EPIC-sICAS 
(NCT02323425),  
HIF-1α RICAMIS (NCT03740971)55 
TNF-α RICAMIS (NCT03740971)55 
IL-1β RICAMIS (NCT03740971)55 
IL-4  
IL-6 RICAMIS (NCT03740971)55, rTPA-RIC 
(NCT02886390), RIC-SIID (NCT04069546)  
IL-10 PICASSO (NCT03208166)  
TLR-2 RIC-SIID (NCT04069546)  
MicroRNA RESIST (NCT03481777) 
HS-CRP rTPA-RIC (NCT02886390), PICASSO 
(NCT03208166)  
bFGF TRIPCAIS (NCT03218293), EPIC-sICAS 
(NCT02323425) 
TEG-MA ChiCTR-INR-17012308   
Platelet reactivity NCT03635177 
Epinephrine NCT04039399 
Norepinephrine NCT04039399 




S100B – S100 calcium-binding protein B  
NSE – Neuron-Specific Enolase 
GFAP – Glial Fibrillary Acidic Protein 
MMP-9 – Matrix metalloproteinase-9 
BDNF – Brain-derived neurotrophic factor 
VEGF – Vascular Endothelial Growth Factor 
HIF-1α – Hypoxia-inducible Factor 1-Alpha 
TNFα – Tumour Necrosis Factor Alpha 
IL-1β – Interleukin 1 Beta 
IL-4 – Interleukin 4 
IL-6 – Interleukin 6 
IL-10 – Interleukin 10 
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TLR-2 – Toll-like Receptor 2 
HS-CRP – High Sensitivity C Reactive Protein 
bFGF – Basic Fibroblast Growth Factor 
TEG-MA – Thromboelastography 
ICAM-1 – Intracellular Adhesion Molecule 1 
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